About The DECIPHER Project

The DECIPHER RNAi screening platform was an open source project created by Cellecta to provide tools for researchers to perform and analyze comprehensive shRNA knockdown screens and to develop a standardized, yet versatile platform for collecting and comparing results from different studies and labs. The DECIPHER RNAi screening platform aided and continues to aid researchers interested in functional annotation of signaling networks, interpretation of viability screening and expression profiling results, and collaboration with other DECIPHER Project members. Development of the DECIPHER libraries was funded in part by several NIH grants (CA098374, NCRR RR024095, NHGRI HG003355, NCI CA134062, NCI CA141848) and distributed in plasmid form to academic and non-profit researchers under MTA at no charge. For a list of participating institutions and publications, visit the DECIPHER Mission page.

Although Cellecta is no longer offering the DECIPHER pooled lentiviral shRNA libraries under MTA, they can be purchased at a discounted rate for academic and non-profit researchers. For more information, see the DECIPHER shRNA Libraries page on the Cellecta website.

Current DECIPHER Project members can access DECIPHER Software and other resources such as the user manual and shRNA library sequences.

Other Projects

NCI supported synthetic lethality RNAi screening and DDR database contract research project, "siRNA Resource for Synthetic Lethal Screening of DNA Repair and Damage Signaling Networks"

A promising direction in the development of anti-cancer drugs with high specificity and low toxicity is the possibility of inhibiting the functions of synthetically lethal (SL) (synergistic) DNA Damage and Repair (DDR) drug targets that are specifically modulated in cancer development. One of the promising, although unrealized, strategies for identifying SL targets is to apply a systematic, unbiased RNAi viability screen based on the ablation of two targets from a complete set of DDR genes. As a first step for constructing a cancer-SL gene interaction map, which used Phase I SBIR contract funding (RFP NO. N44CO27026-9, 290: siRNA Resource for Synthetic Lethal Screening of DNA Repair and Damage Signaling Networks), we developed the technology for the construction of novel bi-specific pooled lentiviral shRNA libraries designed for the combinatorial knockdown of any two targets in a set of rationally selected genes. Furthermore, we successfully demonstrated the application of the bi-specific shRNA library to detect SL binary interactions between 40 DDR genes in an isogenic breast cancer cell model.

Please visit the Bi-Specific SL DDR shRNA Library page for project and ordering information.


The DECIPHER Project was established by Cellecta, Inc. under collaboration and joint grants with the Fred Hutchinson Cancer Research Center, the Roswell Park Cancer Institute, and The Scripps Research Institute. We would like to acknowledge Dr. Gus Frangou from the FHCRC and Dr. Andrei Gudkov of the RPCI for their invaluable contributions and scientific expertise.

We also wish to acknowledge Agilent Technologies for granting us exclusive, early-access to their Oligo Library Synthesis technology for shRNA library applications.

Press Releases

Cellecta launches Bi-Specific SL DDR shRNA Library as a public resource

NCI supported Synergistic Lethality RNAi screening and DDR database contract research project (RFP NO. N44CO27026-9, 290) - 400 DDR database now available

Cellecta receives Phase II contract of NCI supported Synergistic Lethality RNAi screening and DDR database contract research project

Addgene helps distribute DECIPHER
05-17-2011 (PRLog)

DECIPHER Human Module 3 is released
02-24-2011 (PRWeb)

View the DECIPHER Project Launch Press Release
10-28-2010 (PRWeb).